{
  "ticker": "DXB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02963316",
  "id": "02963316",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250630",
  "time": "0833",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250630/pdf/06l7h446ngkmy3.pdf",
  "summary": "- **Milestone Payment Received**: \u00a5400 million (~AU$4.2 million) from FUSO Pharmaceutical Industries Ltd. for clinical site initiation in Japan.  \n- **Potential Future Payments**: Up to \u00a510.5 billion (~AU$107 million) in total milestones (development/sales) and 15-20% royalties on net sales in Japan.  \n- **Global Licensing Deals**: Cumulative potential of ~AU$1.4 billion in upfront/milestone payments across four regional licenses.  \n- **ACTION3 Trial Progress**: Japanese sites accelerating recruitment (~20 patients) for FSGS Phase 3 trial.  \n- **Cash Flow Update**: Over AU$65 million received to date from licensing deals (no closing cash balance disclosed).  \n\n*Omitted: Operational details, forward-looking statements, and background on FSGS/DMX-200.*",
  "usage": {
    "prompt_tokens": 2113,
    "completion_tokens": 175,
    "total_tokens": 2288,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-29T22:46:57.197526"
}